Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry

被引:24
作者
Gabrielsson, Johan [1 ,5 ]
Fjellstrom, Ola [2 ]
Ulander, Johan [2 ]
Rowley, Michael [3 ]
Van der Graaf, Piet H. [4 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Lead Generat, S-43183 Molndal, Sweden
[3] AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden
[4] Pfizer Ltd, Sandwich Res Unit, Dept Pharmacokinet Dynam & Metab PDM & Global Pha, Sandwich CT13 9NJ, Kent, England
[5] AstraZeneca R&D, BAC, S-43183 Molndal, Sweden
关键词
Mechanism-based PKPD modelling; potency; efficacy; lipophilicity; structure-activity relationship; turnover models; effect compartment models; occupancy binding models; PLASMA-PROTEIN BINDING; PHARMACOLOGY; RATS; MODEL; TIME;
D O I
10.2174/156802611794480864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e. g. clearance) and pharmacology (e. g. potency), it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
引用
收藏
页码:404 / 418
页数:15
相关论文
共 22 条
[1]   Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans [J].
Abraham, Anson K. ;
Mager, Donald E. ;
Gao, Xiang ;
Li, Mei ;
Healy, David R. ;
Maurer, Tristan S. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (01) :169-178
[2]   The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics [J].
Agoram, Balaji M. ;
Martin, Steven W. ;
van der Graaf, Piet H. .
DRUG DISCOVERY TODAY, 2007, 12 (23-24) :1018-1024
[3]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[4]   On the Influence of Protein Binding on Pharmacological Activity of Drugs [J].
Berezhkovskiy, Leonid M. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (04) :2153-2165
[6]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[7]  
Danhof M., 2007, COMPREHENSIVE MED 2, P885
[8]   Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology [J].
Gabrielsson, J. ;
Green, A. R. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (03) :767-774
[9]  
Gabrielsson J., 2006, PHARMACOKINETIC PHAR
[10]   Optimising in vivo pharmacology studies-Practical PKPD considerations [J].
Gabrielsson, Johan ;
Green, A. Richard ;
Van der Graaf, Piet H. .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2010, 61 (02) :146-156